6
Oct
2026
INGREDIA SA
Exhibitor at CPHI Milan 2026 stand 16C75, Finished Dosage & Formulation
About Us
Categories
-
Country/Region:France
-
On CPHI since:2019
-
Certificates:3
-
Employees:250 - 499
Company types
Primary activities
Event information
CPHI Milan 2026
-
6 Oct 2026 - 8 Oct 2026
-
Fiera Milano, Italy
-
Visit us at stand 16C75, Finished Dosage & Formulation
Products Featured at CPHI Milan 2026
-
Product Xelflex
Xelflex® is a milk protein hydrolysate with an anti-inflammatory effect. Several studies showed that consumption of dairy products was associated with lower low-grade systemic inflammation. Xelflex®, has a proven efficacy in reducing inflammatory markers and oedema. Xelflex benefits from a consumer study s... -
Product Lactium®
In a world where professional and personal demands are increasing, stress has become an omnipresent phenomenon with a profound impact on physical and mental health. When stress becomes chronic, it not only disrupts emotions and mood, but also affects the ability to sleep well.
Finding effectiv... -
Product Pep2Dia®
For 59% of global consumers*, being in good health is being fit and active. It is also, for 45% of them, to show a healthy waistline. For those, blood sugar management has been a trending topic. Blood sugar management product launches have grown by +113% over the past 5 years**.
Long know...
INGREDIA Resources (1)
-
Video Xelflex®, a bioactive ingredient with joint health benefits
Osteoarthritis is a very common disease, leading to chronic pain, loss of joint function, and reduced mobility: 33 to 50% of people over 65 are affected by mobility loss (Mobility : Harvard Health Publishing®, 2022.)
Xelflex® is a milk protein hydrolysate with anti-inflammatory effect.
Xelflex® benefits from a consumer study showing significant results on pain reduction, improvement of mobility and quality of life.


